Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Legend Biotech Corp ADR’s stock clocked out at $37.66, down -1.98% from its previous closing price of $38.42. In other words, the price has decreased by -$1.98 from its previous closing price. On the day, 1.02 million shares were traded. LEGN stock price reached its highest trading level at $38.465 during the session, while it also had its lowest trading level at $36.85.
Ratios:
To gain a deeper understanding of LEGN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.07 and its Current Ratio is at 5.20. In the meantime, Its Debt-to-Equity ratio is 0.36 whereas as Long-Term Debt/Eq ratio is at 0.35.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Redburn Atlantic on October 08, 2024, initiated with a Buy rating and assigned the stock a target price of $86.
On June 17, 2024, Truist started tracking the stock assigning a Buy rating and target price of $88.
H.C. Wainwright reiterated its Buy rating for the stock on May 24, 2024, while the target price for the stock was revised from $86 to $73.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 23 ’25 when Huang Ying bought 15,291 shares for $45.04 per share.
Yeung Jessie bought 642 shares of LEGN for $28,890 on Jul 23 ’25. On Jun 26 ’25, another insider, Casey Patrick John, who serves as the Director of the company, bought 1,000 shares for $33.23 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 6930531840 and an Enterprise Value of 13218497536. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.51 while its Price-to-Book (P/B) ratio in mrq is 6.81. Its current Enterprise Value per Revenue stands at 18.15 whereas that against EBITDA is -57.89.
Stock Price History:
The Beta on a monthly basis for LEGN is 0.30, which has changed by -0.33825338 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, LEGN has reached a high of $59.62, while it has fallen to a 52-week low of $27.34. The 50-Day Moving Average of the stock is 2.73%, while the 200-Day Moving Average is calculated to be 3.62%.
Shares Statistics:
It appears that LEGN traded 1.73M shares on average per day over the past three months and 1060390 shares per day over the past ten days. A total of 184.03M shares are outstanding, with a floating share count of 181.37M. Insiders hold about 1.44% of the company’s shares, while institutions hold 46.08% stake in the company. Shares short for LEGN as of 1752537600 were 8387958 with a Short Ratio of 4.84, compared to 1749772800 on 14367980. Therefore, it implies a Short% of Shares Outstanding of 8387958 and a Short% of Float of 8.74.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Legend Biotech Corp ADR (LEGN) is currently attracting attention from 4.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.03 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.38 and -$1.11 for the fiscal current year, implying an average EPS of -$0.71. EPS for the following year is $0.68, with 5.0 analysts recommending between $1.71 and $0.29.
Revenue Estimates
In the current quarter, 15 analysts expect revenue to total $228.46M. It ranges from a high estimate of $245M to a low estimate of $215M. As of the current estimate, Legend Biotech Corp ADR’s year-ago sales were $186.52MFor the next quarter, 15 analysts are estimating revenue of $277.64M. There is a high estimate of $320.88M for the next quarter, whereas the lowest estimate is $235M.
A total of 18 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $1.14B, while the lowest revenue estimate was $925.05M, resulting in an average revenue estimate of $1.03B. In the same quarter a year ago, actual revenue was $627.24MBased on 18 analysts’ estimates, the company’s revenue will be $1.56B in the next fiscal year. The high estimate is $1.85B and the low estimate is $1.22B.
